Letaplimab represents a novel therapeutic approach for addressing complement-mediated diseases. This antibody targets C1q, a critical component of the complement cascade, aiming to block its initial engagement. Early https://maciebpzw237082.activoblog.com/52361358/letaplimab-a-innovative-medical-approach